Resveratrol modulates murine collagen-induced arthritis by inhibiting Th17 and B-cell function

Annals of the Rheumatic Diseases

Volumn 71, Issue 1, 2012, Pages 129-135

  Xuzhu, Gao ^a   Komai Koma, Mousa ^a   Leung, Bernard P ^b   Howe, Hwee Siew ^b   McSharry, Charles ^a   McInnes, Iain B ^a   Xu, Damo ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b TAN TOCK SENG HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 17; INTERLEUKIN 4; INTERLEUKIN 6; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; B LYMPHOCYTE; BONE EROSION; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOREGULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TH17 CELL;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, EXPERIMENTAL; AUTOANTIBODIES; B-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED DBA; STILBENES; TH17 CELLS;

EID: 82955235595     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2011.149831     Document Type: Article

References (44)

1. Janossy G, Panayi G, Duke O, et al. Rheumatoid arthritis: a disease of T-lymphocyte/ macrophage immunoregulation. Lancet 1981;2:839-42. (Pubitemid 11017556)
2. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
3. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
4. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006;35:169-74. (Pubitemid 43890735)
5. Stark K, Straub RH, Blazicková S, et al. Genetics in neuroendocrine immunology: implications for rheumatoid arthritis and osteoarthritis. Ann NY Acad Sci 2010;1193:10-14.
6. Kageyama Y, Koide Y, Yoshida A, et al. Reduced susceptibility to collagen-induced arthritis in mice deficient in IFN-gamma receptor. J Immunol 1998;161:1542-8. (Pubitemid 28380588)
7. Chabaud M, Durand JM, Buchs N, et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999;42:963-70. (Pubitemid 29215007)
8. Nakae S, Nambu A, Sudo K, et al. Suppression of immune induction of collageninduced arthritis in IL-17-deficient mice. J Immunol 2003;171:6173-7. (Pubitemid 37467240)
9. Hitchon CA, Alex P, Erdile LB, et al. A distinct multicytokine profile is associated with anti-cyclical citrullinated peptide antibodies in patients with early untreated inflammatory arthritis. J Rheumatol 2004;31:2336-46. (Pubitemid 39603079)
10. Cook AD, Rowley MJ, Mackay IR, et al. Antibodies to type II collagen in early rheumatoid arthritis. Correlation with disease progression. Arthritis Rheum 1996;39:1720-7. (Pubitemid 26331026)
11. Takemura S, Klimiuk PA, Braun A, et al. T cell activation in rheumatoid synovium is B cell dependent. J Immunol 2001;167:4710-18. (Pubitemid 32954353)
12. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81. (Pubitemid 38758544)
13. Schiff M. Abatacept treatment for rheumatoid arthritis. Rheumatology (Oxford) 2011;50:437-49.
14. McInnes IB, Leung BP, Sturrock RD, et al. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat Med 1997;3:189-95. (Pubitemid 27064704)
15. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
16. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85. (Pubitemid 43736578)
17. McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010;69:1898-906.
18. Khanna D, Sethi G, Ahn KS, et al. Natural products as a gold mine for arthritis treatment. Curr Opin Pharmacol 2007;7:344-51. (Pubitemid 46731200)
19. Bertelli AA, Das DK. Grapes, wines, resveratrol, and heart health. J Cardiovasc Pharmacol 2009;54:468-76.
20. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003;17:1975-85. (Pubitemid 37392442)
21. Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992;339:1523-6.
22. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 1998;138:619-20. (Pubitemid 28313808)
23. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003;425:191-6. (Pubitemid 37150899)
24. Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109:2293-302. (Pubitemid 46425866)
25. Das S, Das DK. Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 2007;6:168-73. (Pubitemid 47455785)
26. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007;450:712-16. (Pubitemid 350207685)
27. Imler TJ Jr, Petro TM. Decreased severity of experimental autoimmune encephalomyelitis during resveratrol administration is associated with increased IL-17+IL-10+ T cells, CD4(-) IFN-gamma+ cells, and decreased macrophage IL-6 expression. Int Immunopharmacol 2009;9:134-43.
28. Sánchez-Fidalgo S, Cárdeno A, Villegas I, et al. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur J Pharmacol 2010;633:78-84.
29. Dave M, Attur M, Palmer G, et al. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum 2008;58:2786-97.
30. Shakibaei M, Csaki C, Nebrich S, et al. Resveratrol suppresses interleukin-1beta-induced inflammatory signaling and apoptosis in human articular chondrocytes: potential for use as a novel nutraceutical for the treatment of osteoarthritis. Biochem Pharmacol 2008;76:1426-39.
31. Elmali N, Esenkaya I, Harma A, et al. Effect of resveratrol in experimental osteoarthritis in rabbits. Inflamm Res 2005;54:158-62. (Pubitemid 41178921)
32. Lu B, Solomon DH, Costenbader KH, et al. Alcohol consumption and markers of inflammation in women with preclinical rheumatoid arthritis. Arthritis Rheum 2010;62:3554-9.
33. Nissen MJ, Gabay C, Scherer A, et al. The effect of alcohol on radiographic progression in rheumatoid arthritis. Arthritis Rheum 2010;62:1265-72.
34. Xu D, Jiang HR, Kewin P, et al. IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc Natl Acad Sci U S A 2008;105:10913-18.
35. Issuree PD, Pushparaj PN, Pervaiz S, et al. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J 2009;23:2412-24.
36. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008;453:106-9. (Pubitemid 351630329)
37. Ciolino HP, Daschner PJ, Yeh GC. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res 1998;58:5707-12. (Pubitemid 29006410)
38. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9. (Pubitemid 47300008)
39. Svajger U, Obermajer N, Jeras M. Dendritic cells treated with resveratrol during differentiation from monocytes gain substantial tolerogenic properties upon activation. Immunology 2010;129:525-35.
40. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73. (Pubitemid 19138011)
41. Wirleitner B, Schroecksnadel K, Winkler C, et al. Resveratrol suppresses interferongamma- induced biochemical pathways in human peripheral blood mononuclear cells in vitro. Immunol Lett 2005;100:159-63. (Pubitemid 41262014)
42. Lee M, Kim S, Kwon OK, et al. Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma. Int Immunopharmacol 2009;9:418-24.
43. Sharma S, Chopra K, Kulkarni SK, et al. Resveratrol and curcumin suppress immune response through CD28/CTLA-4 and CD80 co-stimulatory pathway. Clin Exp Immunol 2007;147:155-63. (Pubitemid 44915567)
44. Aggarwal BB, Bhardwaj A, Aggarwal RS, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-840. (Pubitemid 39409568)